↑ Rising
Business
Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals
Amylyx shares surge 55% following positive Phase 3 results for its GLP-1 inhibitor designed to prevent blood sugar crashes.
1 trends tracked about this subject — the full history, oldest to newest below.
Amylyx shares surge 55% following positive Phase 3 results for its GLP-1 inhibitor designed to prevent blood sugar crashes.